Countries Embrace Genome Editing in Contrast of EU’s Opinion November 8, 2018 Agri-Business http://agnetwest.com/countries-genome-editing-contrast-eu/
To fulfill biofuels’ promise, scientists boost plant oils with gene editing November 25, 2018 https://cen.acs.org/energy/biofuels/fulfill-biofuelspromise-scientists-boost-plant/96/i47 ... To Peoples, the future looks promising. A 20% increase in the yield of conventional oil crops like canola and soybean could boost the economic value of these crops by $10 billion, he says. If the current techniques work well in camelina, the company will attempt similar gene edits in canola and soybeans. Although Yield10’s primary goal is to sell its camelina oil for human health products and as an ingredient for agricultural animal feed rather than as a feedstock for biofuels, Peoples says the gene-editing discovery made by Yield10 could be beneficial for that type of application too. Yield10 won’t disclose the exact edits its scientists made to improve camelina’s oil production, citing proprietary information. But presentation slides shared online on Nov. 4 for investors indicate that edits to genes that the firm calls C3008a, C3008b, and C3009 work to increase oil production by simultaneously increasing fatty acid biosynthesis and blocking the metabolism of the synthesized lipid. At the same time, Yield10’s Canadian subsidiary, Metabolix Oilseeds, is working to edit a gene the company has called C3007 in camelina and canola. Gene C3007 encodes a protein that negatively regulates a key enzyme in fatty acid biosynthesis, acetyl-CoA carboxylase. By decreasing the activity of this negative regulator, the firm aims to boost the enzyme’s activity and make more plant oil. ...
Interesting article with direct YTEN mention CRISPR http://www.wbur.org/commonhealth/2018/11/30/gene-edited-food-crispr-crops
Increasing Crop Yield Through Smart Approaches In Trait Discovery December 3, 2018 https://sciencetrends.com/increasing-crop-yield-through-smart-approaches-in-trait-discovery/ In Yield10’s research, the use of these models from the perspective of the company’s trait discovery and development program are detailed extensively, and one day may make significant impacts on the cost and timeline for developing new yield traits for major row crops – all of which could help in the challenge of addressing global food security challenges.
Yield10 twitter account: Yield10 Bioscience @Yield10Bio We are thrilled that the segment in which we participated with @commonhealth / @WBUR on the use of CRISPR and gene/genome editing technologies to impact crop yield, was featured on @HereAndNow! https://www.wbur.org/hereandnow/2018/12/10/gene-edited-food-oversight
Dec 13, 2018 Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor WOBURN, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in a number of leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years. https://yield10bioscienceinc.gcs-we...ence-names-sherri-m-brown-phd-former-monsanto
Jan 15, 2019 Yield10 Bioscience Reports Encouraging Results from 2018 Field Tests of C3003 and Announces Advancement of C3003 into Commercial Development for Canola https://yield10bioscienceinc.gcs-we...-reports-encouraging-results-2018-field-tests
Yield10 Bioscience (YTEN) Now Covered by National Securities Jan 25th, 2019 https://www.modernreaders.com/news/...-yten-now-covered-by-national-securities.html Yield10 Bioscience logoInvestment analysts at National Securities initiated coverage on shares of Yield10 Bioscience (NASDAQ:YTEN) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating and a $5.00 price target on the specialty chemicals company’s stock. Commercial Relationships In Early Stages. Since late 2017, two research license agreements have been reached with Monsanto and Forage Genetics International, major players in the soybean and sorghum markets, respectively. While these are research agreements for now, we believe these announcements validate Yield10’s technology and represent the kind of relationships that could generate commercial revenue. High Ceiling Value. Between the value of the IP portfolio in the near term, and the potential value provided by commercial revenue streams, we believe shares of Yield10 could prove to be materially undervalued at current levels. Should commercialization agreements materialize, we believe our twelve month price target could prove to be conservative.”
YTEN Investor Presentation February 2019 http://ir.yield10bio.com/static-files/a105a7f1-3979-4775-8f62-fc417942a29f
GM-No? Yield10 Bioscience is Developing Gene-Edited Corn for Increased Yields By Catherine Lamb - February 25, 2019 https://thespoon.tech/gm-no-yield10-bioscience-is-developing-gene-edited-corn-for-increased-yields/
Aug 12, 2019 Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001 WOBURN, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office allowing its patent application covering the use of C4001 to improve productivity in crops. https://yield10bioscienceinc.gcs-we...cience-announces-notice-allowance-us-patent-0
In the past few weeks I bought some YTEN shares again. I am hoping for some good news in next few months. Aug. 12, 2019 Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/42...ples-q2-2019-results-earnings-call-transcript “CBD is a good example of a product targets for Yield10's traits and capabilities that considerable value for third-party with deep knowledge of the medical CBD business. Yet we're seeing a funded R&D program and upfront payments research funding and license revenues, as appropriate. These product targets provide opportunities for Yield10 to develop businesses that generate product revenue and/or partnerships of downstream revenue. We will keep you posted as it continues to make progress and finalize the business cases.” “And we're also actively engaged in discussions with third parties interested in deploying our traits in a variety of other commercially important crops. We plan to keep you updated on the progress we're making all of these areas in the second half 2019.”
Interesting items raised in the National Research report. Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities Thursday, September 12th, 2019 Lars Charter https://rivertonroll.com/news/2019/...ives-buy-rating-from-national-securities.html The firm currently has a $5.00 price target on the specialty chemicals company’s stock. Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes. A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology. No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market. Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote.
Besides their cooperation with Bayer/Monsanto, YTEN has also granted a Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum. Forage Genetics is a subsidiary of Land O’Lakes, Inc. According to Wikipedia the annual revenue of Land O’Lakes is $15 Billion. Hopefully there is more to come. Link: http://ir.yield10bio.com/node/14091/pdf
Oct 23, 2019 Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop https://yield10bioscienceinc.gcs-we...signs-research-agreement-j-r-simplot-evaluate
J. R. Simplot Company is another big win for YTEN. This further validates YTEN’s technology. J. R. Simplot Company is a multi-billion company and a big player for potatoes. https://en.wikipedia.org/wiki/Simplot Among others J. R. Simplot Company is a big supplier of french fries to McDonald's.
I am confident that we are near the bottom. YTEN has research licenses with three multi billion companies, namely with Bayer/Monsanto, with Forage Genetics (a subsidiary of Land O’Lakes, Inc.) and recently with J. R. Simplot Company. In my opinion there is much business potential in the future.
